Epub: Amato et al. Treatment of cognitive impairment in multiple sclerosis: position paper. J Neurol. 2012 Nov.
Cognitive impairment in MS is common, debilitating and burdensome. Key evidence from trials was reviewed to enable recommendations to be made to guide clinical practice and research. Behavioural and pharmacological interventions on cognition reported in published studies were reviewed. Most studies evaluating behavioural treatment for impairment in learning and memory, deficits of attention and executive function have demonstrated some improvement. Controlled studies in RRMS indicate interferon (IFN) β-1b and IFN β-1a were associated with modest cognitive improvement.
“In addition to progressive MS symptomatic treatments on the next frontier in improving the live of MSers. Top of the pile are fatigue and cognitive impairment. Both of these problems are the main driver of early disability in MSers, these manifest in the unemployment rate and inter-personal relationship breakdowns that are much higher than you would expect for the level of physical disability. We need to focus on the hidden symptoms of MS if we are to make inroads into the socioeconomic impact of this disease.”